











## Licensed products in pre-clinical & clinical phases

Reference	Indication/ Use	R+D	Pre-clinical	Phase I	Phase II	Phase III	Licensed	Research group
EYE-SCAFF project	LSCD syndrome						 ferrer	<a href="#">CB06/01/0003</a>
Procedure for the procurement of solid micro- or nanoparticles	Administration of medicines						 nanomol Technologies	<a href="#">CB06/01/0033</a>
Targeted delivery of therapeutic molecules to CXCR4 cells	Colorectal cancer						NANOLIGENT	<a href="#">CB06/01/0014</a> <a href="#">CB06/01/1031</a>
Nanostructured proteins	Cancer						NANOLIGENT	<a href="#">CB06/01/0014</a> <a href="#">CB06/01/1031</a>
Therapeutic nanoconjugates (1)	Cancer					<b>To download</b>	NANOLIGENT	<a href="#">CB06/01/0014</a> <a href="#">CB06/01/1031</a>
Therapeutic nanoconjugates (2)	Cancer						NANOLIGENT	<a href="#">CB06/01/0014</a> <a href="#">CB06/01/1031</a>
Scaffold Proteins and Therapeutic Nanoconjugates	Cancer						NANOLIGENT	<a href="#">CB06/01/0014</a> <a href="#">CB06/01/1031</a>